Oricell Therapeutics raised additional capital in a pre-IPO round as the Shanghai-based CAR-T developer accelerates plans for a public listing. The company said it has raised more than $110 million in total, framing the financing as runway extension and preparation for capital-market milestones. Oricell’s lead program is Ori-C101, a GPC3-targeted autologous CAR-T for hepatocellular carcinoma (HCC). The company reported that a Phase 1 study testing three dose levels among 10 patients showed an objective response in the highest-dose cohort, and it is now planning further studies toward its goal of achieving the first globally approved CAR-T in HCC. Beyond Ori-C101, Oricell described a broader pipeline that includes next-generation modalities, including in vivo CAR-T programs. The financing underscores sustained investor demand for solid-tumor CAR-T risk-taken at earlier stages, particularly when early efficacy signals are presented alongside a defined regulatory endgame.